LENZ - NASDAQ
LENZ Therapeutics, Inc.
$7.01
-0.14%LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
At a Glance
Live SnapshotLENZ Therapeutics, Inc. Management Team
Mr. Shawn Olsson
Chief Commercial Officer
Compensation
$532,133
Mr. Daniel R. Chevallard CPA
Chief Financial Officer
Compensation
$680,368
Mr. Marc G. Odrich M.D.
Chief Medical Officer
Compensation
$732,250
Mr. James W. McCollum
Co-Founder & Director
Compensation
$31,209
Mr. Evert B. Schimmelpennink
President, Chief Executive Officer, Secretary & Director
Compensation
$1,071,375
Ms. Melissa Rosness
Senior Vice President of Manufacturing Operations
Kris Gambelin
Senior Vice President of Regulatory & Clincal Operations
Ms. Breianna Bowen
Vice President of Human Resources
Mr. David Choromanski
Vice President of Marketing
Mr. Domenick Porfidia
Vice President of Sales
LENZ Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $654K and sold $108K worth of LENZ shares, resulting in $546K of net buying activity.
3 Months
41.2K
365.57K
0
0.00
+366K
+$366K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
12.7K
288.84K
4.2K
108.41K
+180K
+$180K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Schimmelpennink Evert B.
Director, Officer: President, Ceo And Secretary
$251K
Mccollum James W
Director
$239K
Chevallard Daniel R.
Officer: Chief Financial Officer
$114K
George Jeffrey P.
Director
$50K
Top Sellers
Olsson Shawn
Officer: Chief Commercial Officer
$108K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $546K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
4 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
LENZ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 12, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | June 06, 2023 | July 19, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 21, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.